| ObjectiveJoint anti-viral treatment of chronic hepatitis B treatment is an important direction, this article on recombinant human interferon-α2b combined with thymosin-α1 treatment HBeAg positive chronic hepatitis B virus therapy for clinical research, the goal is to improve the sustained response rate and prevent or reduce drug-resistant mutations.Methods1 Study object248 cases of CHB patients with 149 cases of male,99 cases of female, includes 125 cases of HBeAg-positive chronic hepatitis B patients,123 cases of HBeAg-negative chronic hepatitis B patients. HBVDNA are all positive.2 GroupingIn accordance with the ratio of 1:1 will recombinant human interferon were randomly divided into two groups:recombinant human interferon group and recombinant human interferon combined with thymosin a1 group (combination group); 124 cases patients of recombinant human interferon group include 78 cases of male,46 cases of female, age among 19 years old to 58 years old, average age is 39±5.69 years old; Of which include 62 cases HBeAg-positive chronic hepatitis B,62 cases HBeAg-negative chronic hepatitis B in.124 cases of the joint group include 71 cases of male,53 cases of female, age among 17 years old to 59 years old, average age is 37±8.96 years old; Of which include 63 cases HBeAg-positive chronic hepatitis B,61 cases HBeAg-negative chronic hepatitis B in. Between the two groups demographic characteristics and clinical characteristics of statistical treatment, there are no significant difference (P>0.05), are comparable.3 Test Test the serum HBV markers of the two groups patients (HBsAg, HBsAb, HBeAg, HBeAb, HBcAb), HBVDNA, liver function indicators, CD4/CD8T lymphocyte subsets count before and after treatment, in which serum HBV markers (HBsAg, HBsAb, HBeAg, HBeAb, HBcAb) is tested using ELISA, HBVDNA is tested by fluorescence. quantitative polymerase chain reaction (PCR) method; Liver function is tested using biochemical analyzer Shanghai Roche automatic instrument; CD4/CD8T count lymphocyte subsets is tested by American Co.BD flow cytometry instrument; Histopathology diagnostic criterion referenced literature. The length of liver tissue>1.5 cm, the internal structure includes at least three complete portal tracts. Conventional producers, HE, Masson staining and HBsAg, HBcAg immunohistochemical staining by the two pathology physicians after reading the results of pathological diagnosis. Delineation of diagnostic criteria for pathological grading of inflammation and fibrosis G0～4 stages S0～4. At the same time, the system according to Knodell Histology on liver activity index (HAI) score. In the above-mentioned projects, specific projects are:test of immunological indicators:HBsAg, anti-HBs, HBeAg, anti-HBe, anti-HBc, anti-HBc-lgM, anti-HBc-lgG, PreS1Ag, PreS1-Ab, PreS2Ag, PreS2Ab and HBV-DNA and so on. Non-specific projects are:blood, urine, liver function tests and so on.4 Statistical analysesThe statistical analyses was made using by SPSS11.0 software, include t-test, chi-square test and u-test. Test standard a=0.05.Results1 Negative rate of HBVDNAAfter treatment of 48 weeks,96 cases of the joint group,58 cases of the Recombinant Human Interferon group's HBVDNA are negative; the joint group and the Recombinant Human Interferon group's HBV markers (HBeAg positive, HBeAg negative, the two together) are there significant differences (x2=10.241, x2=11.248, x2=22.527, both P<0.05); 2 The seroconversion rate of HBeAgRecombinant Human Interferon group of 62 cases of HBeAg positive HBeAg seroconversion rate is 27.42%, the joint group of 63 cases of HBeAg positive HBeAg seroconversion rate is 30.16%, there is no significant difference (x2=1.522, P>0.05).3 Normalization rate of ALTAfter 48 weeks, the normalization rate of ALT between the joint group and the recombinant human interferon group is significant difference.(P<0.05).4 Negative rate of Pre-Sl antigenRecombinant human interferon group after treatment with the joint group Pre-S 1 antigen-negative rate of contrast:after 48 weeks of the treatment, the total Pre-S1 antigen-negative rate, the joint group is 26.67%(28/125),recombinant human interferon group is 13%(16/123), there is significant difference(x2=5.124, P<0.05), prompted anti-viral therapy for 48 weeks will enable the Pre-Sl antigen negative, but in patients with HBeAg-positive Pre-Sl antigen conversion rate of the joint group is 20.05% and the recombinant human interferon group is 18.18%, is no significant difference (x2=1.091, P>0.05); The rate of HBeAg-negative patients with Pre-Sl antigen negative of the joint group is 26.67%, of the recombinant human interferon is 7.02%,there is also significant difference (x2=6.0122, P<0.05).5 Subsets and the ratio of CD4/CD8T count of lymphocyteThe two groups before and after treatment CD4/CD8T count of lymphocyte subsets and the ratio of change (x±s):Before treatment, the joint group and the recombinant human interferon group's CD4, CD8, CD4/CD8 were no significantly difference (P=0.2011), are comparable; after treatment, the joint group and the recombinant human interferon group CD4, CD4/CD8 are significantly difference (P<0.05), CD8 is no significant difference(P>0.05).Conclusion 1 Recombinant human interferon a2b combination therapy with thymosin al efficacy of CHB can improve the sustained response rate and reduce drug-resistant mutations.2 Prolong anti-virus time can improve the sustained response rate.
|
PDF Full Text Request